Combination treatment with extracorporeal photopheresis, interferon alfa and interleukin-2 in a patient with the Sezary syndrome

British Journal of Dermatology

Volumn 140, Issue 6, 1999, Pages 1144-1147

  Fritz, T M ^a   Kleinhans, M ^a   Nestle, F O ^a   Burg, G ^a   Dummer, R ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Combination treatment; Cutaneous T cell lymphoma; Extracorporeal photopheresis; Interferon alfa; Interleukin 2; Sezary syndrome

Indexed keywords

CHLORAMBUCIL; CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT INTERLEUKIN 2; RETINOID; VINCRISTINE;

ADULT; ARTICLE; CASE REPORT; FEMALE; FEVER; FLU LIKE SYNDROME; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MULTIMODALITY CANCER THERAPY; NAUSEA; PRIORITY JOURNAL; PSOAS ABSCESS; PUVA; SEPSIS; SEZARY SYNDROME; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

BIOLOGICAL RESPONSE MODIFIERS; COMBINED MODALITY THERAPY; FEMALE; HUMANS; INTERFERON-ALPHA; INTERLEUKIN-2; MIDDLE AGED; PHOTOPHERESIS; SEZARY SYNDROME; SKIN NEOPLASMS;

EID: 0033048902     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2133.1999.02889.x     Document Type: Article

References (25)

1. 1 Willemze R, van Vloten WA, Hermans J et al. Diagnostic criteria in Sézary's syndrome: a multiparameter study of peripheral blood lymphocytes in 32 patients with erythroderma. J Invest Dermatol 1983; 81: 392-7.
2. 2 Nestle FO, Häffner AC, Hess Schmid M et al. Moderne Therapiekonzepte bei kutanen Lymphomen. Schweiz Med Wochenschr 1997; 127: 311-20.
3. 3 Dummer R, Häffner AC, Hess M, Burg G. A rational approach to the therapy of cutaneous T-cell lymphoma. Onkologie 1996; 19: 226-30.
4. 4 Kaye FJ, Bunn PA, Steinberg SM et al. A randomised trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. N Engl J Med 1989; 321: 1784-90.
5. 5 Lamberg SI, Green SB, Byar DP et al. Clinical staging for cutaneous lymphoma. Ann Int Med 1984; 100: 187-92.
6. 6 Edelson R, Berger C, Gasparro F et al. Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy: preliminary results. N Engl J Med 1987; 316: 297-303.
7. 7 Demierre MF, Foss FM, Koh HK. Proceedings of the International Consensus Conference on Cutaneous T-Cell Lymphoma (CTCL) Treatment Recommendations, Boston, MA, Oct 1 and 2 1994.
8. 8 Edelson RP, Heald P, Perez M et al. Photopheresis update. Prog Dermatol 1991; 25: 1-6.
9. 9 Fraser-Andrews E, Seed P, Whittaker S, Russell-Jones R. Extracorporeal photopheresis in Sézary syndrome. No significant effect in the survival of 44 patients with a peripheral T-cell clone. Arch Dermatol 1998; 134: 1001-5.
10. 10 Rook AH, Prystowsky MB, Cassin M et al. Combined therapy for Śzary syndrome with extracorporeal photochemotherapy and low-dose interferon alfa therapy. Arch Dermatol 1991; 127: 1535-40.
11. 11 Heald PW, Perez MI, Christensen I et al. Photopheresis therapy of cutaneous T-cell lymphoma: the Yale-New Haven hospital experience. Yale J Biol Med 1989; 62: 629-38.
12. 12 Heald P, Rook AH, Perez M et al. Treatment of crythrodermic cutaneous T-cell lymphoma with extracorporeal photochemotherapy. J Am Acad Dermatol 1992; 27: 427-33.
13. 13 Rook AH, Nahass GT, Macelis BJ et al. Extracorporeal photochemotherapy in the treatment of cutaneous T cell lymphoma and autoimmune disorders affecting the skin. In: Photosensitising Compounds: Their Chemistry, Biology and Clinical Use, Ciba Foundation Symposium, No. 146. New York: John Wiley & Sons, 1989: 171-7.
14. 14 Vowels BR, Cassin M, Boufal M et al. Extracorporeal photochemotherapy induces production of tumor necrosis factor and IL-6 by adherent peripheral blood mononuclear cells. J Invest Dermatol 1991; 96: 585.
15. 15 Gottlieb SL, Wolfe JT, Fox FE et al. Treatment of cutaneous T-cell lymphoma with extracorporeal photopheresis monotherapy and in combination with recombinant interferon alfa: a 10-year experience at a single institution. J Am Acad Dermatol 1996; 35: 946-57.
16. 16 Dunn PA, Ihde DC, Foon KA. The role of recombinant interferon alfa-2a in the therapy of cutaneous T-cell lymphoma. Cancer 1986; 57: 1689-95.
17. 17 Olsen EA, Rosen ST, Vollmer RT et al. Interferon alfa-2a in the treatment of cutaneous T-cell lymphoma. J Am Acad Dermatol 1989; 20: 395-407.
18. 18 Herbermann RB, Ortaldo JR, Djeu JY et al. Role of interferon regulation of cytotoxicity by natural killer cells and macrophages. Ann NY Acad Sci 1980; 350; 63-71.
19. 19 Bunn PA, Hoffman StJ, Norris D et al. Systemic therapy of cutaneous T-cell lymphomas (mycosis fungoides and the Sézary syndrome). Ann Int Med 1994; 121: 592-602.
20. 20 Rajan GP, Seifert B, Prümmer O et al. Incidence and in-vivo relevance of anti-interferon antibodies during treatment of low-grade cutaneous T-cell lymphomas with interferon alpha-2a combined with acitretin or PUVA. Arch Dermatol Res 1996; 288: 543-8.
21. 21 Rook AH, Gottlieb SL, Wolfe JT et al. Pathogenesis of cutaneous T-cell lymphoma: implications for the use of recombinant cytokines and photopheresis. Clin Exp Immunol 1997; 107 (Suppl. 1): 16-20.
22. 22 Dummer R, Heald PW, Nestle FO et al. Sézary syndrome T-cell clones display T-helper 2 cytokines and express the accessory factor-1 (interferon-γ receptor β-chain). Blood 1996; 88: 1383-9.
23. 23 Dummer R, Welters H, Keilholz U et al. Interleukin-2: immunologischer Hintergrund und klinische Anwendung in der Tumortherapie. Hautarzt 1990; 41: 53-5.
24. 24 Gisselbrecht C, Maraninchi D, Pico JL, et al. Interleukin-2 treatment in lymphoma: a phase II multicenter study. Blood 1994; 83: 2081-5.
25. 25 Boehncke WH, Gerdes J, Wiese M et al. A majority of proliferating T cells in cutaneous malignant T cell lymphomas may lack the high affinity IL-2 receptor (CD25). Arch Dermatol Res 1993; 285: 127-30.